What is the ADCS-ADL and what does it measure?

The Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) is a 23-item caregiver-rated instrument that measures functional independence in daily activities in patients with Alzheimer's disease and other dementias. Scores range from 0 (fully dependent) to 78 (fully independent).

How is ADCS-ADL scored and interpreted?

Higher ADCS-ADL scores indicate better preserved function; lower scores indicate greater functional dependence. Scores should be interpreted longitudinally — declining serial scores document progressive functional impairment, while stable scores may indicate treatment efficacy.

Who developed the ADCS-ADL?

ADCS-ADL was developed by Douglas Galasko and colleagues through the Alzheimer's Disease Cooperative Study (ADCS) network. The original validation study was published in Alzheimer Disease and Associated Disorders in 1997.

Is ADCS-ADL used in clinical trials?

Yes. ADCS-ADL is widely used as a primary or co-primary endpoint in Phase 2 and Phase 3 Alzheimer's disease clinical trials, including pivotal studies for cholinesterase inhibitors, memantine, and newer disease-modifying therapies.

What is the reference period for ADCS-ADL scoring?

ADCS-ADL asks the informant to assess the patient's performance over the past 4 weeks, reflecting recent functional status rather than a single-day observation.

What activities are assessed by ADCS-ADL?

ADCS-ADL covers 23 activities including: eating, dressing, bathing, toileting, walking, using the telephone, shopping, preparing simple meals, paying bills, using appliances, managing medications, handling correspondence, and watching television/engaging in hobbies.

Is ADCS-ADL sensitive to change in mild Alzheimer's disease?

Standard ADCS-ADL has ceiling effects in mild AD, where patients may score near maximum despite early functional impairment. The ADCS-ADL-MCI version was developed specifically for MCI and mild AD, including more complex instrumental tasks to improve sensitivity at this stage.

How does ADCS-ADL compare to the Bristol ADL scale?

Both instruments assess functional ADL in dementia using caregiver informant reporting. ADCS-ADL has stronger evidence as a clinical trial endpoint and is more widely used in international research. Bristol ADL (20 items) is more commonly used in UK clinical practice.

Can ADCS-ADL be used to determine care needs or funding?

While ADCS-ADL was designed as a research and clinical monitoring tool rather than a formal care needs assessment, low ADCS-ADL scores documenting significant functional dependence can support applications for home care services or residential care funding.

What rate of ADCS-ADL decline is typical in untreated Alzheimer's disease?

Studies of untreated or placebo-treated mild-to-moderate AD patients typically show ADCS-ADL declines of 3–6 points per year. Rates vary by disease stage, with steeper declines in moderate disease than in mild disease.

Is ADCS-ADL appropriate for Lewy body or vascular dementia?

ADCS-ADL is most validated in Alzheimer's disease. It can be applied in other dementias for clinical monitoring purposes, but interpretation should be contextualised given the different functional profiles of Lewy body dementia (fluctuating) and vascular dementia (step-wise decline).

Online Medical Tools — ADCS-ADL

Printed on 9/4/2026

For informational purposes only. This is not medical advice.

Geriatrics

ADCS-ADL

ADCS-ADL is a structured caregiver/informant assessment of daily functioning often used in dementia clinics and Alzheimer disease trials. Totals are interpreted longitudinally, where lower scores over time generally indicate worsening functional dependence.

Formula: ADCS-ADL total is a summed functional score (commonly represented on a 0-78 range), with higher values indicating better function.

ADCS-ADL total score

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Administer to a Regular Caregiver or Informant

ADCS-ADL is completed by a caregiver who has observed the patient's daily activities over the past 4 weeks. The informant should have sufficient contact to reliably judge performance — ideally someone living with or providing daily care to the patient.

Rate 23 Daily Living Activities

The caregiver rates 23 basic and instrumental ADL items including: eating, dressing, bathing, toileting, walking, using the telephone, shopping, housekeeping, managing finances, using household appliances, preparing food, medication management, and other complex daily tasks. Each item is scored based on the level of performance and assistance required.

Sum Scores and Track Over Time

Total ADCS-ADL scores range from 0 to 78, where higher scores indicate better preserved functional independence. Serial scores are more informative than single measurements — declining scores document progressive functional impairment, while stable or improving scores may indicate treatment efficacy.

Who Uses the ADCS-ADL

Alzheimer's Disease Clinical Trial Endpoint

Clinical researchers and pharmaceutical investigators

ADCS-ADL was specifically designed as a functional outcome measure for Alzheimer's disease treatment trials and is used as a primary or co-primary endpoint in regulatory submission studies for AD therapeutics.

Dementia Specialist Follow-Up Assessment

Geriatricians, neurologists, and dementia nurses

Serial ADCS-ADL scores at clinic visits provide objective documentation of functional trajectory, supporting treatment decision-making and goals-of-care discussions with patients and families.

Caregiver Needs Assessment

Social workers and aged care coordinators

Low ADCS-ADL scores quantify functional dependence and caregiver burden, informing decisions about respite services, home care package level, and readiness for residential care transition.

Cognitive-Functional Correlation Analysis

Neuropsychologists and cognitive researchers

ADCS-ADL scores correlate with cognitive test performance across dementia stages. Comparing functional decline rates to cognitive decline rates provides insight into the specific ADL domains most affected by cognitive deterioration.

Treatment Monitoring for AD Pharmacotherapy

Prescribing physicians and dementia pharmacists

For patients on cholinesterase inhibitors or other AD-modifying therapies, ADCS-ADL tracks whether functional performance is stabilising, slowing its rate of decline, or continuing to deteriorate despite treatment.

Pro Tips

Score Based on Actual Performance, Not Capability

ADCS-ADL measures what the patient actually does in daily life, not what they could do if prompted or assisted. If a patient used to pay bills but no longer does because a family member does it for them, this should be scored as impaired regardless of theoretical capability.

Establish Premorbid Functional Baseline

Some ADCS-ADL items (e.g., managing finances, using appliances) may never have been performed by certain patients due to lifelong patterns rather than dementia. Document premorbid ADL patterns to distinguish true functional decline from never-performed activities.

Higher Scores Are Better — Not Worse

ADCS-ADL is scored in the direction of preserved function: 78 = fully independent across all activities, 0 = complete dependence. Ensure clinicians and data entry staff understand this directionality to avoid score interpretation errors.

Serial Scores Over at Least 6 Months Are Most Informative

Single ADCS-ADL scores have limited interpretive value without comparison to a prior baseline. Establish baseline early in the clinical relationship and measure at 6–12-month intervals to capture meaningful trajectory.

Separate Basic and Instrumental ADL Subscores

ADCS-ADL includes both basic ADLs (eating, bathing, dressing, toileting, walking) and instrumental ADLs (finances, shopping, appliances). Tracking subscores separately reveals whether impairment is progressing from higher-order instrumental tasks toward more fundamental self-care.

Match Informant to the Most Knowledgeable Observer

If multiple carers provide care across different domains (e.g., one family member assists with medications, another with finances), identify the most knowledgeable informant for each domain or use the primary daily carer for the whole assessment.

Use ADCS-ADL-MCI for Early-Stage Patients

The standard ADCS-ADL has ceiling effects in mild dementia. The ADCS-ADL-MCI (23-item version designed for MCI and mild AD) includes more complex instrumental tasks and is more sensitive for early functional change in clinical trial settings.

Interpret Alongside Cognitive and Behavioural Measures

Functional decline (ADCS-ADL decline) interpreted alongside cognitive decline (MMSE or ADAS-Cog) and behavioural symptoms (NPI-Q) provides a complete picture of disease burden. Functional decline without proportionate cognitive change may suggest comorbid depression, pain, or deconditioning.

Common Questions About Your Results

Evidence-Based Methodology

ADCS-ADL is a widely used functional endpoint in Alzheimer disease research and longitudinal clinical follow-up.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: Dementia Functional Outcomes Review 2026.04
Source set version:: ADCS-ADL source set v1

How to Interpret Your Result

Higher ADCS-ADL totals indicate better retained daily function; declining serial scores suggest progressive functional impairment.

When to Use This Tool

Use when caregiver-informed functional tracking is needed in Alzheimer disease or related dementia follow-up.

Limitations

Scale versions vary by study/context and scoring depends on informant reliability and patient-caregiver interaction level.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Sources

Changelog

April 21, 2026 · v1.0.0
Added ADCS-ADL trust metadata and first changelog entry for versioned maintenance.

Related Tools